Overexpression of CXCR4, CXCL12 and CXCR7 as a therapeutic approach to restore sensitivity to novel agents in multiple myeloma.

Overexpression of CXCR4, CXCL12 and CXCR7 as a therapeutic approach to restore sensitivity to novel agents in multiple myeloma. - CXCR4

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00009348

Enrollment

130

Registered

2015-10-22

Start date

2010-02-01

Completion date

Unknown

Last updated

2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C90.0

Interventions

Group 1: The aim of this study was to analyze the CXCL12/CXCR4-axis and to examine the efficacy of targeting CXCR4/CXCL12 mediated adhesion to the BM. AMD3100 (CXCR4 antagonist) and NOX-A12 (anti-CXCL

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients with multiple myeloma.

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

Measure	Time frame
Since the interaction of malignant plasma cells with the bone marrow is fundamental for multiple myeloma pathogenesis, the aim of our study was to analyze the CXCL12/CXCR4-axis and to examine the efficacy of targeting CXCR4/CXCL12 mediated adhesion to the bone marrow including effects on adhesion molecules.	—

Countries

Germany

Contacts

Public ContactMonika Engelhardt Engelhardt

Uniklinik Freiburg

monika.engelhardt@uniklinik-freiburg.de+49 761 270 32460

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Mar 14, 2026